IMPEDIMED LIMITED — Capital/Financing Update 2015

Jul 13, 2015

==> picture [108 x 100] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

14 July 2015

ASX ANNOUNCEMENT

6th Major Cancer Centre in US Commercial L-Dex[®] Pilot Program

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), is pleased to announce the addition of another L-Dex commercial pilot with a prominent multidisciplinary cancer centre in the US. This is the 2[nd] pilot involving a multidisciplinary cancer care organisation and the 6 of six planned large cancer centre pilots prior to full commercial US launch.

This latest pilot is with one of the nation’s largest collaborative networks of medical professionals devoted exclusively to treating cancer. Clinicians in this group routinely share best practices, contribute to research strategies, and help shape public policy.

“Expansion of the cancer centre pilot program for L-Dex to this multidisciplinary organisation fits perfectly with our commercial launch strategy”, stated Managing Director and CEO Richard Carreon. “Full integration into the complete patient care continuum will maximise the benefit of L-Dex to cancer patients.”

The pilot program activities include integrating a prospective surveillance model for the early detection of cancer related lymphoedema using L-Dex, capturing L-Dex scores in the electronic medical records (EMR), and providing education and training for staff, patients, and referring physicians. This multidisciplinary pilot program will offer additional vital insight into our market for the full commercial launch of L-Dex in the US scheduled for later in calendar year 2015.

Richard Carreon Managing Director & CEO

For further information contact: Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 1 of 1